![]() This is because multi-targeted treatments can lead to therapeutic benefits both by enhancing the treatment efficacy and by avoiding the acquisition of monotherapy resistance ( 6). With these improvements, SynergyFinder 2.0 is expected to greatly extend its potential applications in various areas of multi-drug combinatorial screening and precision medicine.ĭrug combinations have become a standard therapy for various complex diseases, including tuberculosis, malaria, HIV, and most of the advanced cancers ( 1–5). A number of additional improvements were also implemented based on the user requests, including new visualization and export options, updated user interface, as well as enhanced stability and performance of the web-tool. Here, we describe the latest version of SynergyFinder (release 2.0), which has extensively been upgraded through the addition of novel features supporting especially higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns, along with automated outlier detection procedure, extended curve-fitting functionality and statistical analysis of replicate measurements. cell lines or primary patient-derived cells), and for better understanding of mechanisms of combination treatment efficacy or resistance. Since its first release in 2017, SynergyFinder has become a widely used web-tool both for the discovery of novel synergistic drug combinations in pre-clinical model systems (e.g. SynergyFinder ( ) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |